Product logins

Find logins to all Clarivate products below.


Major Depressive Disorder (DSM-V) – Epidemiology – Epidemiology – Major Depressive Disorder (DSM V) – Mature Markets

Clarivate Epidemiology’s coverage of major depressive disorder (MDD) (DSM-V) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets. We report the prevalence of MDD (DSM-V) for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan. In addition to forecasting prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy in the major mature pharmaceutical markets.

Clarivate Epidemiology’s MDD (DSM-V) forecast will answer the following questions:

  • Of all people with MDD (DSM-V), how many in each of the major mature pharmaceutical markets have been formally diagnosed?
  • Of all people diagnosed with MDD (DSM-V), how many in each of the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of MDD (DSM-V) over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graph depicting the patient flow between or within different disease states for the major mature pharmaceutical markets. These patient-flow diagrams are provided at the regional level but may be requested for any specific country or forecast year.

Clarivate Epidemiology forecasts the following MDD (DSM-V) patient populations:

  • Total lifetime prevalent cases.
  • Total 12-month prevalent cases.

Note: Coverage may vary by country.

Related Market Assessment Reports

Report
Schizophrenia – Landscape & Forecast – Disease Landscape & Forecast (G7)
The schizophrenia therapy market remains very competitive; atypical and typical antipsychotics play a dominant role. While the continued generic erosion of atypical antipsychotics influences…
Report
Glaucoma – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of glaucoma comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy…
Report
Binge Eating Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Binge Eating Disorder (US)
Binge eating disorder (BED) is a prevalent condition in the United States; it affects millions of individuals across diverse demographics. BED is characterized by recurrent episodes of excessive…
Report
Bipolar Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Bipolar Depression (US)
Among bipolar disorder (BPD) patients, depressive episodes are typically more common than manic or mixed episodes; symptoms of bipolar depression include fatigue, insomnia, suicidal ideation, and…
Report
Post-Traumatic Stress Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Post-Traumatic Stress Disorder (US)
Multiple guidelines recommend treating post-traumatic stress disorder (PTSD) first with psychotherapy. However, such approaches do not suffice for many patients, necessitating the use of…